A new topical Janus kinase inhibitor, delgocitinib ointment, has shown potential effectiveness in treating moderate-to-severe atopic dermatitis (AD). This study set out to assess the efficacy and safety of the ointment in a Japanese population with AD.
Learn more at the Journal of the American Academy of Dermatology.